https://gabrailcancercenter.com/a-first-in-human-phase-1-2-open-label-multicentre-dose-escalation-and-expansion-trial-of-vert-002-in-locally-advanced-or-metastatic-solid-tumors-including-nsclc-with-met-alterations/ 2026-09-11T15:16:01+00:00 https://gabrailcancercenter.com/a-phase-1-2a-open-label-study-of-sa53-os-an-mdm2-inhibitor-in-locally-advanced-or-metastatic-p53-wild-type-solid-tumors/ 2026-09-11T15:15:18+00:00 https://gabrailcancercenter.com/a-phase-1-2a-multicenter-open-label-first-in-human-study-of-db-1311-in-advanced-metastatic-solid-tumors/ 2026-09-11T15:14:33+00:00 https://gabrailcancercenter.com/an-open-label-multicenter-multi-arm-phase-1-study-of-adu-1805-in-adults-with-advanced-solid-tumors/ 2026-09-11T15:13:39+00:00 https://gabrailcancercenter.com/a-phase-1-2-open-label-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-inx-315-in-advanced-cancer/ 2026-09-11T15:12:56+00:00 https://gabrailcancercenter.com/a-first-in-human-multicenter-phase-1-open-label-study-of-xtx301-in-advanced-solid-tumors/ 2026-09-11T15:12:12+00:00 https://gabrailcancercenter.com/a-randomized-placebo-controlled-parallel-phase-2a-dose-ranging-study-of-topical-ht-001-for-skin-toxicities-associated-with-epidermal-growth-factor-receptor-inhibitor/ 2026-09-11T15:11:34+00:00 https://gabrailcancercenter.com/a-phase-1b-2-single-arm-open-label-dose-escalation-study-of-chiauranib-for-advanced-solid-malignant-tumors-and-relapsed-refractory-small-cell-lung-cancer/ 2026-09-11T15:10:40+00:00 https://gabrailcancercenter.com/a-phase-1-2a-multicenter-open-label-first-in-human-study-of-db-1303-bnt323-in-advanced-metastatic-solid-tumors/ 2026-09-11T15:10:07+00:00 https://gabrailcancercenter.com/a-phase-1-study-of-im-1021-in-participants-with-advanced-malignancies/ 2026-09-11T15:09:26+00:00 https://gabrailcancercenter.com/a-phase-1a-1b-open-label-dose-escalation-and-dose-expansion-study-of-ubx-303061-in-relapsed-refractory-b-cell-malignancies/ 2026-09-11T14:58:43+00:00 https://gabrailcancercenter.com/a-phase-1-open-label-multicenter-dose-escalation-study-of-sgr-1505-as-monotherapy-in-mature-b-cell-malignancies/ 2026-09-11T14:58:04+00:00 https://gabrailcancercenter.com/a-phase-3-randomized-double-blind-add-on-study-of-navtemadlin-plus-ruxolitinib-vs-placebo-plus-ruxolitinib-in-jak-inhibitor-naive-myelofibrosis-with-suboptimal-response-to-ruxolitinib/ 2026-09-11T14:57:12+00:00 https://gabrailcancercenter.com/an-open-label-multicenter-phase-1b-2-study-of-krt-232-combined-with-ruxolitinib-in-primary-myelofibrosis-post-pv-mf-or-post-et-mf-with-suboptimal-response-to-ruxolitinib/ 2026-09-11T14:56:06+00:00 https://gabrailcancercenter.com/a-phase-2-randomized-open-label-study-of-momelotinib-in-participants-with-anemia-due-to-low-risk-myelodysplastic-syndrome/ 2026-09-11T14:55:14+00:00 https://gabrailcancercenter.com/a-phase-3-randomized-double-blind-placebo-controlled-study-of-elritercept-ker-050-for-transfusion-dependent-anemia-in-very-low-low-or-intermediate-risk-myelodysplastic-syndromes-renew/ 2026-09-11T14:53:17+00:00 https://gabrailcancercenter.com/a-phase-3-randomized-open-label-study-of-belantamab-mafodotin-with-lenalidomide-and-dexamethasone-brd-vs-daratumumab-lenalidomide-and-dexamethasone-drd-in-newly-diagnosed-multiple-myeloma-inel/ 2026-09-11T14:52:21+00:00 https://gabrailcancercenter.com/a-single-arm-open-label-phase-2-study-of-subcutaneous-isatuximab-via-on-body-delivery-system-with-weekly-carfilzomib-and-dexamethasone-in-relapsed-and-or-refractory-multiple-myeloma-rrmm/ 2026-09-11T14:50:42+00:00 https://gabrailcancercenter.com/a-protocol-to-assess-the-safety-efficacy-and-pharmacokinetics-of-continuous-subcutaneous-low-dose-lenalidomide-star-lld-for-the-treatment-of-multiple-myeloma/ 2026-09-11T14:50:05+00:00 https://gabrailcancercenter.com/a-phase-1-2-open-label-multicentre-dose-escalation-and-expansion-study-of-belantamab-as-monotherapy-and-in-combination-with-other-treatments-in-multiple-myeloma/ 2026-09-11T14:48:08+00:00 https://gabrailcancercenter.com/a-multicenter-randomized-double-blind-adaptive-phase-2-3-study-of-eik1001-and-pembrolizumab-vs-placebo-and-pembrolizumab-as-first-line-therapy-in-advanced-melanoma/ 2026-09-11T14:47:31+00:00 https://gabrailcancercenter.com/a-phase-3-randomised-double-blind-placebo-controlled-multicentre-trial-comparing-trilaciclib-versus-placebo-in-limited-stage-small-cell-lung-cancer/ 2026-09-11T14:46:52+00:00 https://gabrailcancercenter.com/a-phase-3-randomized-open-label-trial-of-trastuzumab-deruxtecan-with-pembrolizumab-vs-platinum-based-chemotherapy-with-pembrolizumab-as-first-line-therapy-in-her2-overexpressing-pd-l1-tps-50-no/ 2026-09-11T14:46:14+00:00 https://gabrailcancercenter.com/a-multicenter-randomized-open-label-phase-2-study-of-bms-986504-monotherapy-in-advanced-or-metastatic-nsclc-with-homozygous-mtap-deletion-after-progression-on-prior-therapies/ 2026-09-11T14:37:43+00:00 https://gabrailcancercenter.com/an-open-label-randomized-controlled-phase-3-study-of-sigvotatug-vedotin-with-pembrolizumab-vs-pembrolizumab-monotherapy-as-first-line-treatment-in-pd-l1-high-advanced-nsclc-be6a-lung-02/ 2026-09-11T14:35:05+00:00 https://gabrailcancercenter.com/a-phase-2-3-multisite-randomized-master-protocol-for-a-global-trial-of-bnt327-in-combination-with-chemotherapy-and-other-investigational-agents-in-first-line-non-small-cell-lung-cancer/ 2026-09-11T14:34:07+00:00 https://gabrailcancercenter.com/a-phase-1-dose-escalation-study-of-the-tolerability-safety-efficacy-and-pharmacokinetics-of-zg006-in-small-cell-lung-cancer/ 2026-09-11T14:33:20+00:00 https://gabrailcancercenter.com/efficacy-safety-of-olvimulogene-nanivacirepvec-platinum-doublet-physicians-choice-of-immune-checkpoint-inhibitor-compared-to-docetaxel-in-nsclc-viro-25/ 2026-09-11T14:19:07+00:00 https://gabrailcancercenter.com/a-study-assessing-kb707-for-the-treatment-of-advanced-solid-tumor-malignancies-affecting-the-lungs/ 2026-09-11T14:15:45+00:00 https://gabrailcancercenter.com/an-open-label-phase-2b-global-multicenter-cohort-trial-of-zipalertinib-in-locally-advanced-or-metastatic-nsclc-with-exon-20-insertion-and-uncommon-single-or-compound-egfr-mutations/ 2026-09-11T14:15:06+00:00 https://gabrailcancercenter.com/a-phase-1-2-trial-of-quaratusugene-ozeplasmid-and-atezolizumab-maintenance-therapy-in-extensive-stage-small-cell-lung-cancer-es-sclc/ 2026-09-11T14:13:36+00:00 https://gabrailcancercenter.com/a-phase-1-2-open-label-dose-escalation-study-of-quaratusugene-ozeplasmid-in-combination-with-osimertinib-in-advanced-egfr-mutant-metastatic-nsclc-that-progressed-after-osimertinib/ 2026-09-11T14:11:52+00:00 https://gabrailcancercenter.com/a-phase-3-randomized-double-blind-placebo-controlled-study-of-bleximenib-venetoclax-and-azacitidine-for-newly-diagnosed-aml-harboring-kmt2a-rearrangements-or-npm1-mutations-ineligible-for-intensive/ 2026-09-11T14:10:46+00:00 https://gabrailcancercenter.com/a-phase-1b-2-open-label-study-of-apvo436-in-combination-with-venetoclax-and-azacitidine-in-newly-diagnosed-acute-myeloid-leukemia-aml/ 2026-09-11T14:09:29+00:00 https://gabrailcancercenter.com/a-phase-1b-study-of-the-pharmacokinetics-safety-and-efficacy-of-orally-administered-hqp1351-in-subjects-with-refractory-chronic-myeloid-leukemia/ 2026-09-11T14:07:14+00:00 https://gabrailcancercenter.com/a-phase-1-open-label-multicenter-study-of-the-pharmacokinetics-and-safety-of-pralatrexate-in-advanced-solid-tumor-or-hematological-malignancy-with-normal-or-mild-moderate-severe-hepatic-impairment/ 2026-09-11T14:06:22+00:00 https://gabrailcancercenter.com/a-randomized-multi-center-double-blinded-placebo-controlled-trial-of-xembify-plus-standard-medical-treatment-vs-placebo-to-prevent-infections-in-hypogammaglobulinemia-with-cll-multiple-myeloma-an/ 2026-09-11T14:04:10+00:00 https://gabrailcancercenter.com/an-open-label-phase-1-2-study-evaluating-immunomodulatory-avm0703-in-patients-with-lymphoid-malignancies-the-opal-study/ 2026-09-11T14:02:48+00:00 https://gabrailcancercenter.com/a-randomized-double-blind-placebo-controlled-phase-3-study-to-evaluate-dostarlimab-as-sequential-therapy-after-chemoradiation-in-locally-advanced-unresected-head-and-neck-squamous-cell-carcinoma-ja/ 2026-09-11T14:01:27+00:00 https://gabrailcancercenter.com/a-randomized-open-label-phase-3-study-of-amivantamab-folfiri-versus-cetuximab-bevacizumab-folfiri-in-kras-nras-and-braf-wild-type-recurrent-unresectable-or-metastatic-colorectal-cancer-after-pri/ 2026-09-11T14:00:53+00:00 https://gabrailcancercenter.com/a-randomized-open-label-phase-3-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-kras-nras-and-braf-wild-type-unresectable-or-metastati/ 2026-09-10T18:37:07+00:00 https://gabrailcancercenter.com/substudy-aspen-09-03-a-single-arm-phase-2-study-of-evorpacept-with-trastuzumab-and-chemotherapy-in-metastatic-her2-positive-breast-cancer-aspen-09-03-protocol-at148009/ 2026-09-10T18:36:24+00:00 https://gabrailcancercenter.com/a-phase-2-open-label-study-of-pcs6422-with-capecitabine-in-patients-with-advanced-or-metastatic-breast-cancer/ 2026-09-10T18:35:05+00:00 https://gabrailcancercenter.com/randomized-open-label-study-of-the-bria-imt-regimen-and-checkpoint-inhibitor-vs-physicians-choice-in-advanced-metastatic-breast-cancer-bria-abc/ 2026-09-10T18:34:29+00:00